Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Breast Neoplasms
  • Pyrazoles
  • Receptor, ErbB-2
  • Sulfonamides

abstract

  • Celecoxib combined with trastuzumab is well tolerated. However, this combination in patients with HER2/neu-overexpressing, trastuzumab-refractory disease, was not active.

publication date

  • July 15, 2004

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-03-0463

PubMed ID

  • 15217939

Additional Document Info

start page

  • 4062

end page

  • 7

volume

  • 10

number

  • 12 I